{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.33","upperLimit":"-3.63","value":"-4.481"},{"groupId":"OG001","lowerLimit":"-4.17","upperLimit":"-2.50","value":"-3.337"}]}],"title":"Neurotoxicity wk 12 change baseline (n=212,240)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.49","upperLimit":"-3.64","value":"-4.564"},{"groupId":"OG001","lowerLimit":"-5.61","upperLimit":"-3.86","value":"-4.739"}]}],"title":"Neurotoxicity wk 24 change baseline (n=148,174)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.52","upperLimit":"-1.79","value":"-3.158"},{"groupId":"OG001","lowerLimit":"-3.64","upperLimit":"-0.627","value":"-2.133"}]}],"title":"Neurotoxicity wk 48 change baseline (n=35,26)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.94","upperLimit":"-2.64","value":"-3.29"},{"groupId":"OG001","lowerLimit":"-2.58","upperLimit":"-1.32","value":"-1.952"}]}],"title":"Physical wellbeing wk 12 chge (n=215,240)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.74","upperLimit":"-2.35","value":"-3.044"},{"groupId":"OG001","lowerLimit":"-2.92","upperLimit":"-1.60","value":"-2.259"}]}],"title":"Physical wellbeingwk 24 chge (n=150,176)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.08","upperLimit":"-0.992","value":"-2.037"},{"groupId":"OG001","lowerLimit":"-1.03","upperLimit":"1.439","value":"0.203"}]}],"title":"Physical wellbeing wk 48 chge (n=38,26)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-12.2","upperLimit":"-8.86","value":"-10.573"},{"groupId":"OG001","lowerLimit":"-8.55","upperLimit":"-5.19","value":"-6.874"}]}],"title":"Trial Outcomes wk 12 chge (n=209,236)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-11.7","upperLimit":"-7.98","value":"-9.84"},{"groupId":"OG001","lowerLimit":"-10.7","upperLimit":"-7.13","value":"-8.894"}]}],"title":"Trial Outcomes wk 24 chge (n=148,173)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-9.28","upperLimit":"-3.98","value":"-6.633"},{"groupId":"OG001","lowerLimit":"-5.76","upperLimit":"0.122","value":"-2.821"}]}],"title":"Trial Outcomes wk 48 chge (n=35,26)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-8.23","upperLimit":"-5.09","value":"-6.658"},{"groupId":"OG001","lowerLimit":"-5.64","upperLimit":"-2.57","value":"-4.106"}]}],"title":"FACT-G Total wk 12 chge (n=213,240)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.84","upperLimit":"-4.31","value":"-6.076"},{"groupId":"OG001","lowerLimit":"-6.30","upperLimit":"-2.92","value":"-4.609"}]}],"title":"FACT-G Totalwk 24 chge (n=147,175)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.29","upperLimit":"-0.118","value":"-2.704"},{"groupId":"OG001","lowerLimit":"-4.42","upperLimit":"1.547","value":"-1.435"}]}],"title":"FACT-G Total wk 48 chge (n=37,26)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-13.3","upperLimit":"-9.03","value":"-11.176"},{"groupId":"OG001","lowerLimit":"-9.64","upperLimit":"-5.41","value":"-7.524"}]}],"title":"FACT/GOGNTX Total wk 12 chge (n=206,230)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-12.9","upperLimit":"-8.23","value":"-10.581"},{"groupId":"OG001","lowerLimit":"-9.64","upperLimit":"-5.41","value":"-9.179"}]}],"title":"FACT/GOGNTX Total wk 24 chge (n=146,172)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-9.24","upperLimit":"-2.50","value":"-5.871"},{"groupId":"OG001","lowerLimit":"-6.92","upperLimit":"0.614","value":"-3.151"}]}],"title":"FACT/GOGNTX Total wk 48 chge (n=35,26)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"381"}],"units":"Participants"}],"description":"Chronic Illness Therapy (FACIT) Measurement System and focuses on four general quality of life domains for physical well being, functional well-being, social/family well-being, and emotional well-being, and includes additional items to characterize treatment-related neurotoxicity. Higher subscales/total scores represent higher QOL. In the case of the neurotoxicity subscale, lower scores correspond to higher neurotoxicity. The recall period referenced in the questionnaire is the past 7 days.Ranges for FACT-G subscales are as follows:.PWB, scale 0 -28, , NtxS scale 0-44, FACT/GOG-Ntx trial outcome index scale is 0-100 and FACT-G scale is also scaled 0-100. An increase from baseline in these scores indicate improvement.","dispersionType":"95% Confidence Interval","groups":[{"description":"Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"OG000","title":"Panobinostat + Bortezomib"},{"description":"Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"OG001","title":"Placebo + Bortezomib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"12, 24 and 48 weeks","title":"Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System : FACT/GOG-NTX-Change From Baseline by Treatment Group","type":"SECONDARY","unitOfMeasure":"score on a scale"}